SG11201509738RA - Methods of treatment and compositions with xanthine oxidase inhibitors - Google Patents

Methods of treatment and compositions with xanthine oxidase inhibitors

Info

Publication number
SG11201509738RA
SG11201509738RA SG11201509738RA SG11201509738RA SG11201509738RA SG 11201509738R A SG11201509738R A SG 11201509738RA SG 11201509738R A SG11201509738R A SG 11201509738RA SG 11201509738R A SG11201509738R A SG 11201509738RA SG 11201509738R A SG11201509738R A SG 11201509738RA
Authority
SG
Singapore
Prior art keywords
compositions
treatment
methods
xanthine oxidase
oxidase inhibitors
Prior art date
Application number
SG11201509738RA
Other languages
English (en)
Inventor
Lhanoo Gunawardhana
Vijay Gupte
Himanshu Naik
Michael Mayer
Kanji Komatsu
Original Assignee
Takeda Pharmaceuticals Usa Inc
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Usa Inc, Teijin Pharma Ltd filed Critical Takeda Pharmaceuticals Usa Inc
Publication of SG11201509738RA publication Critical patent/SG11201509738RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201509738RA 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors SG11201509738RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US201361839609P 2013-06-26 2013-06-26
PCT/US2014/040286 WO2014194226A2 (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Publications (1)

Publication Number Publication Date
SG11201509738RA true SG11201509738RA (en) 2015-12-30

Family

ID=50983231

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201509738RA SG11201509738RA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors
SG10201709955PA SG10201709955PA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201709955PA SG10201709955PA (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Country Status (9)

Country Link
US (2) US20140357683A1 (enExample)
JP (2) JP2016520133A (enExample)
CN (1) CN105579037A (enExample)
CA (1) CA2913755A1 (enExample)
MX (1) MX2015016494A (enExample)
PH (1) PH12015502679A1 (enExample)
SG (2) SG11201509738RA (enExample)
TW (1) TW201536284A (enExample)
WO (1) WO2014194226A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105769766B (zh) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 一种托匹司他纳米乳及其制备方法
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
EP3957629B1 (en) 2016-07-18 2023-09-06 Arthrosi Therapeutics, Inc. Process for making deuterated hydroxy-benzbromarone and intermediates thereof
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
AU2020287549A1 (en) * 2019-06-04 2022-01-27 Nippon Chemiphar Co., Ltd. Therapeutic for gout or hyperuricemia
JP7668386B2 (ja) * 2021-06-15 2025-04-24 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
CN115252567A (zh) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 非布司他渗透泵缓释片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
ES2505690T3 (es) 2002-03-28 2014-10-10 Teijin Pharma Limited Preparación sólida que contiene una forma única de cristal de un derivado de ácido tiazolcarboxílico
DK1757610T3 (da) 2004-06-14 2011-08-01 Nippon Chemiphar Co Kondenseret pyrimidinderivat og xanthinoxidaseinhibitor
JP5040656B2 (ja) 2005-10-07 2012-10-03 アステラス製薬株式会社 トリアリールカルボン酸誘導体
AU2008206231A1 (en) * 2007-01-19 2008-07-24 Takeda Pharmaceuticals U.S.A., Inc. Methods for preventing or reducing the number of gout flares using xanthine oxidoreductase inhibitors and anti-inflammatory agents
KR101772963B1 (ko) 2009-03-31 2017-08-31 깃세이 야쿠힌 고교 가부시키가이샤 인돌리진 유도체 및 그 의약용도
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
ES2669184T3 (es) * 2010-06-16 2018-05-24 Takeda Pharmaceuticals U.S.A., Inc. Nuevas formas de dosificación de liberación modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
CN102641255A (zh) * 2012-05-08 2012-08-22 南方医科大学 一种治疗痛风的非布索坦渗透泵控释片及其制备方法

Also Published As

Publication number Publication date
JP2016520133A (ja) 2016-07-11
CA2913755A1 (en) 2014-12-04
SG10201709955PA (en) 2018-01-30
US20180311217A1 (en) 2018-11-01
WO2014194226A2 (en) 2014-12-04
US20140357683A1 (en) 2014-12-04
PH12015502679A1 (en) 2016-03-07
TW201536284A (zh) 2015-10-01
WO2014194226A3 (en) 2015-05-14
JP2019108356A (ja) 2019-07-04
MX2015016494A (es) 2016-11-18
CN105579037A (zh) 2016-05-11

Similar Documents

Publication Publication Date Title
IL255269A (en) Preparations of obeticholic acid and methods of use
GB201320723D0 (en) Composition and methods of treatment
SG11201601412XA (en) Compositions and methods for the treatment of presbyopia
IL259801A (en) ezh2 inhibitors and methods of using them
HUE055662T2 (hu) Laktát-dehidrogenáz kismolekulás inhibitorai és alkalmazási eljárásai
ZA201601701B (en) Inhibitors of erk and methods of use
SG11201504022RA (en) Glutamase inhibitors and method of use
SG10201709955PA (en) Methods of treatment and compositions with xanthine oxidase inhibitors
EP3016652A4 (en) Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
PT3021839T (pt) Composições para o tratamento da fibrose
IL243728A0 (en) Rorc2 inhibitory trobicycloaryls and methods of using them
IL240695A0 (en) nme inhibitors and methods of using nme inhibitors
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
IL245123A0 (en) Short interfering RNA and its use in methods and preparations for preventing the expression of the orai1 gene
SG11201603506PA (en) Treatment of damaged nerve with pten inhibitor
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
EP3102567A4 (en) Inhibitors of paxillin function and related compositions and methods
GB201312311D0 (en) Uses of enzyme inhibitors
PT3083848T (pt) Composição e método para madeira ou derivados de madeira
GB201310349D0 (en) Composition and method of use thereof
GB201301928D0 (en) Composition and method of use thereof
GB201409466D0 (en) Urea compounds and their use as enzyme inhibitors